Literature DB >> 23435460

Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells.

Brian A Walker1, Christopher P Wardell, David C Johnson, Martin F Kaiser, Dil B Begum, Nasrin B Dahir, Fiona M Ross, Faith E Davies, David Gonzalez, Gareth J Morgan.   

Abstract

Translocations in myeloma are thought to occur solely in mature B cells in the germinal center through class switch recombination (CSR). We used a targeted captured technique followed by massively parallel sequencing to determine the exact breakpoints in both the immunoglobulin heavy chain (IGH) locus and the partner chromosome in 61 presentation multiple myeloma samples. The majority of samples (62%) have a breakpoint within the switch regions upstream of the IGH constant genes and are generated through CSR in a mature B cell. However, the proportion of CSR translocations is not consistent between cytogenetic subgroups. We find that 100% of t(4;14) are CSR-mediated; however, 21% of t(11;14) and 25% of t(14;20) are generated through DH-JH recombination activation gene-mediated mechanisms, indicating they occur earlier in B-cell development at the pro-B-cell stage in the bone marrow. These 2 groups also generate translocations through receptor revision, as determined by the breakpoints and mutation status of the segments used in 10% and 50% of t(11;14) and t(14;20) samples, respectively. The study indicates that in a significant number of cases the translocation-based etiological events underlying myeloma may arise at the pro-B-cell hematological progenitor cell level, much earlier in B-cell development than was previously thought.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23435460     DOI: 10.1182/blood-2012-12-471888

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing.

Authors:  Dörte Wren; Brian A Walker; Monika Brüggemann; Mark A Catherwood; Christiane Pott; Kostas Stamatopoulos; Anton W Langerak; David Gonzalez
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

Review 2.  Molecular basis of clonal evolution in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2020-02-06       Impact factor: 2.490

Review 3.  Genetics of multiple myeloma: another heterogeneity level?

Authors:  Jill Corre; Nikhil Munshi; Hervé Avet-Loiseau
Journal:  Blood       Date:  2015-01-27       Impact factor: 22.113

Review 4.  Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Joseph D Tario; Paul K Wallace
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

Review 5.  Genomic complexity of multiple myeloma and its clinical implications.

Authors:  Salomon Manier; Karma Z Salem; Jihye Park; Dan A Landau; Gad Getz; Irene M Ghobrial
Journal:  Nat Rev Clin Oncol       Date:  2016-08-17       Impact factor: 66.675

6.  Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma.

Authors:  L Melchor; A Brioli; C P Wardell; A Murison; N E Potter; M F Kaiser; R A Fryer; D C Johnson; D B Begum; S Hulkki Wilson; G Vijayaraghavan; I Titley; M Cavo; F E Davies; B A Walker; G J Morgan
Journal:  Leukemia       Date:  2014-01-13       Impact factor: 11.528

7.  Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets.

Authors:  Gina Y Kim; Ana Gabrea; Yulia N Demchenko; Leif Bergsagel; Anna V Roschke; W Michael Kuehl
Journal:  Genes Chromosomes Cancer       Date:  2014-03-03       Impact factor: 5.006

8.  Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

Authors:  Xing-Ding Zhang; Veerabhadran Baladandayuthapani; Heather Lin; George Mulligan; Bin Li; Dixie-Lee W Esseltine; Lin Qi; Jianliang Xu; Walter Hunziker; Bart Barlogie; Saad Z Usmani; Qing Zhang; John Crowley; Antje Hoering; Jatin J Shah; Donna M Weber; Elisabet E Manasanch; Sheeba K Thomas; Bing-Zong Li; Hui-Han Wang; Jiexin Zhang; Isere Kuiatse; Jin-Le Tang; Hua Wang; Jin He; Jing Yang; Enrico Milan; Simone Cenci; Wen-Cai Ma; Zhi-Qiang Wang; Richard Eric Davis; Lin Yang; Robert Z Orlowski
Journal:  Cancer Cell       Date:  2016-04-28       Impact factor: 31.743

9.  A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma.

Authors:  Hakim Bouamar; Saman Abbas; An-Ping Lin; Long Wang; Daifeng Jiang; Kenneth N Holder; Marsha C Kinney; Scott Hunicke-Smith; Ricardo C T Aguiar
Journal:  Blood       Date:  2013-06-17       Impact factor: 22.113

10.  Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.

Authors:  N Puig; M E Sarasquete; A Balanzategui; J Martínez; B Paiva; H García; S Fumero; C Jiménez; M Alcoceba; M C Chillón; E Sebastián; L Marín; M A Montalbán; M V Mateos; A Oriol; L Palomera; J de la Rubia; M B Vidriales; J Bladé; J J Lahuerta; M González; J F S Miguel; R García-Sanz
Journal:  Leukemia       Date:  2013-07-17       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.